This gave me the biggest laugh I've ever had on a message board considering what the two of us have been posting for the past 6 months, here is just one of them:
biotech2010 Friday, 02/03/17 02:21:22 PM
Re: gss2003 post# 2709
Post #
2711
of 3097 Go
I've been a shareholder since 2009 and have closely followed the developments since then-you don't have to explain the various potential paths as a way to deflect my pointed criticism of Traber and his approach to both GALT and his shareholders.
First you say that a positive results for cancer is a $50+ share price, something that is absurd.
Then you say they are in discussions with pharma about partnering, then ignore my direct quote from Traber that all they have done is approach pharma and present data. Do you realize how many small companies do the same thing with big pharma on a daily basis?
The whole cancer study is based on Portland Medical Center funding the very limited program, if Traber had any belief that this would be helpful he would have put money towards it.
The whole Atopic Dermatitis study is THREE patients, there is no way that is significant enough to move the needle for a partnership, particularly when you find (as I have done by reading prior studies with other drugs) that there is enormous variation in the results for other drugs in treating this.
At the end of the day the whole company is based on the CX trial, which is a blind study with only 1/3 of the patients receiving the highest dose (8 mg/kg).
News 
Market Data 
Discover 
